vs
STANDARD BIOTOOLS INC.（LAB）与Maiden Holdings, Ltd.（MHLA）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Maiden Holdings, Ltd.的1.4倍（$19.6M vs $14.0M），Maiden Holdings, Ltd.净利率更高（-61.5% vs -177.4%，领先115.9%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -51.4%），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -21.5%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
梅登控股有限公司是一家注册于百慕大的控股企业，旗下拥有多家保险子公司，面向全球财产及意外险市场提供专项再保险产品，目前业务运营子公司分布在美国、欧洲与百慕大地区。
LAB vs MHLA — 直观对比
营收规模更大
LAB
是对方的1.4倍
$14.0M
营收增速更快
LAB
高出39.9%
-51.4%
净利率更高
MHLA
高出115.9%
-177.4%
两年增速更快
LAB
近两年复合增速
-21.5%
损益表 — Q3 FY2025 vs Q1 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $14.0M |
| 净利润 | $-34.7M | $-8.6M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | -42.1% |
| 净利率 | -177.4% | -61.5% |
| 营收同比 | -11.5% | -51.4% |
| 净利润同比 | -28.8% | -692.5% |
| 每股收益（稀释后） | $-0.09 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABMHLA
| Q3 25 | $19.6M | — | ||
| Q2 25 | $21.8M | — | ||
| Q1 25 | $40.8M | $14.0M | ||
| Q4 24 | — | $11.6M | ||
| Q3 24 | $22.1M | $14.5M | ||
| Q2 24 | $22.5M | $20.5M | ||
| Q1 24 | $45.5M | $28.9M | ||
| Q4 23 | $28.2M | $25.2M |
净利润LABMHLA
| Q3 25 | $-34.7M | — | ||
| Q2 25 | $-33.5M | — | ||
| Q1 25 | $-26.0M | $-8.6M | ||
| Q4 24 | — | $-158.0M | ||
| Q3 24 | $-26.9M | $-34.5M | ||
| Q2 24 | $-45.7M | $-10.0M | ||
| Q1 24 | $-32.2M | $1.5M | ||
| Q4 23 | $-19.8M | $-20.8M |
毛利率LABMHLA
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — | ||
| Q4 23 | 47.6% | — |
营业利润率LABMHLA
| Q3 25 | -168.5% | — | ||
| Q2 25 | -118.1% | — | ||
| Q1 25 | -80.8% | -42.1% | ||
| Q4 24 | — | 2103.0% | ||
| Q3 24 | -120.9% | -243.1% | ||
| Q2 24 | -134.5% | -53.7% | ||
| Q1 24 | -132.2% | 3.0% | ||
| Q4 23 | -75.9% | -84.2% |
净利率LABMHLA
| Q3 25 | -177.4% | — | ||
| Q2 25 | -153.7% | — | ||
| Q1 25 | -63.8% | -61.5% | ||
| Q4 24 | — | 2125.8% | ||
| Q3 24 | -122.0% | -238.1% | ||
| Q2 24 | -203.3% | -48.7% | ||
| Q1 24 | -70.6% | 5.0% | ||
| Q4 23 | -70.2% | -82.4% |
每股收益（稀释后）LABMHLA
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.07 | $-0.09 | ||
| Q4 24 | — | $-1.57 | ||
| Q3 24 | $-0.07 | $-0.35 | ||
| Q2 24 | $-0.12 | $-0.10 | ||
| Q1 24 | $-0.27 | $0.01 | ||
| Q4 23 | $-0.24 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $28.7M |
| 总债务越低越好 | — | $254.8M |
| 股东权益账面价值 | $399.7M | $37.6M |
| 总资产 | $539.6M | $1.2B |
| 负债/权益比越低杠杆越低 | — | 6.78× |
8季度趋势，按日历期对齐
现金及短期投资LABMHLA
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | $28.7M | ||
| Q4 24 | — | $25.7M | ||
| Q3 24 | $210.6M | $110.0M | ||
| Q2 24 | $269.8M | $24.8M | ||
| Q1 24 | $287.1M | $20.7M | ||
| Q4 23 | $51.7M | $35.4M |
总债务LABMHLA
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $254.8M | ||
| Q4 24 | — | $254.8M | ||
| Q3 24 | $55.2M | $254.7M | ||
| Q2 24 | $55.1M | $254.7M | ||
| Q1 24 | $55.0M | $254.6M | ||
| Q4 23 | $63.5M | $254.6M |
股东权益LABMHLA
| Q3 25 | $399.7M | — | ||
| Q2 25 | $424.5M | — | ||
| Q1 25 | $454.6M | $37.6M | ||
| Q4 24 | — | $45.2M | ||
| Q3 24 | $489.3M | $208.2M | ||
| Q2 24 | $510.3M | $238.0M | ||
| Q1 24 | $577.3M | $249.4M | ||
| Q4 23 | $-148.1M | $249.2M |
总资产LABMHLA
| Q3 25 | $539.6M | — | ||
| Q2 25 | $557.0M | — | ||
| Q1 25 | $579.6M | $1.2B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | $681.5M | $1.4B | ||
| Q2 24 | $708.7M | $1.4B | ||
| Q1 24 | $777.7M | $1.5B | ||
| Q4 23 | $323.1M | $1.5B |
负债/权益比LABMHLA
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 6.78× | ||
| Q4 24 | — | 5.64× | ||
| Q3 24 | 0.11× | 1.22× | ||
| Q2 24 | 0.11× | 1.07× | ||
| Q1 24 | 0.10× | 1.02× | ||
| Q4 23 | — | 1.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-21.1M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABMHLA
| Q3 25 | $-22.2M | — | ||
| Q2 25 | $-20.7M | — | ||
| Q1 25 | $-30.3M | $-21.1M | ||
| Q4 24 | — | $-67.4M | ||
| Q3 24 | $-27.9M | $-3.8M | ||
| Q2 24 | $-39.0M | $-23.4M | ||
| Q1 24 | $-62.5M | $8.0M | ||
| Q4 23 | $-14.1M | $6.2M |
自由现金流LABMHLA
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — | ||
| Q4 23 | $-14.1M | — |
自由现金流率LABMHLA
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — | ||
| Q4 23 | -50.2% | — |
资本支出强度LABMHLA
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — | ||
| Q4 23 | 0.3% | — |
现金转化率LABMHLA
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.52× | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
MHLA
暂无分部数据
